[Beta-adrenergic receptor blockers in the treatment of chronic heart failure].
We present a current opinion about the management of chronic heart failure with beta-blocking agents. Pathophysiologic rationales for such treatment and clinical experience were analyzed. Most of the studies showed that long-term treatment of heart failure with beta-blockade produces improvement in symptoms, exercise tolerance, ejection fraction and central hemodynamics (CI, PCWP, MPAP, LVSWI, SVI). Treatment must be started at an extremely low dose and then must be increased gradually to therapeutic levels over several weeks. The titration phase must take place in the hospital. It was emphasized that the management of chronic heart failure with beta-blockers is not the routine management yet. Ongoing multicenters trials should finally determine the place of beta-blockers in the treatment of chronic heart failure.
Mularek-Kubzdela
T
T
I Kliniki Kardiologii A.M. im. K. Marcinkowskiego w Poznaniu.
Grajek
S
S
Cieśliński
A
A
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005080:Exercise Test; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D013318:Stroke Volume / Q000187:drug effects
D000319:Adrenergic beta-Antagonists
Leki blokujace receptory beta-adrenergiczne w leczeniu przewlekłej niewydolności krazenia.